諾華製藥(NVS)將以31億美元收購Anthos

金吾財訊

2025/02/11

金吾財訊 | 黑石集團(BX)旗下黑石生命科學公司和Anthos治療公司宣佈諾華製藥(NVS)將以31億美元收購Anthos，交易預計將於2025年上半年完成。Anthos股東將獲得9.25億美元的首付款。

對於諾華而言，此次收購是其在心血管領域的重要佈局。諾華在心血管領域根基深厚，而阿貝拉西單抗的加入有望進一步豐富其產品線，為全球數百萬面臨中風高風險的心房顫動患者提供更有效的治療選擇。

Anthos 首席執行官 Bill Meury 表示：「諾華在心血管領域的深厚底蘊，使其在推進阿貝拉西單抗的臨牀開發以及將這一創新產品帶給醫療服務提供者和患者方面，具有得天獨厚的優勢。」

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2510841878"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510841878\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510841878?lang=zh_TW&edition=fundamental","thumbnail":"https://static.szfiu.com/news/20210625/ZTg0OWM0M2E2YjcwZGM0MTQ1YzIxNjI0NjAwNDk2ODM0.jpg","is_english":false,"pubTime":"2025-02-11 14:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510841878","market":"other","top_or_hot":-1,"title":"諾華製藥(NVS)將以31億美元收購Anthos","media":"金吾財訊","content":"<html><body><p>金吾財訊 | <a href=\"https://laohu8.com/S/BX\">黑石</a>集團(BX)旗下黑石生命科學公司和Anthos治療公司宣佈<a href=\"https://laohu8.com/S/NVS\">諾華</a>製藥(NVS)將以31億美元收購Anthos，交易預計將於2025年上半年完成。Anthos股東將獲得9.25億美元的首付款。</p><p>對於諾華而言，此次收購是其在心血管領域的重要佈局。諾華在心血管領域根基深厚，而阿貝拉西單抗的加入有望進一步豐富其產品線，為全球數百萬面臨中風高風險的心房顫動患者提供更有效的治療選擇。</p><p>Anthos 首席執行官 Bill Meury 表示：「諾華在心血管領域的深厚底蘊，使其在推進阿貝拉西單抗的臨牀開發以及將這一創新產品帶給醫療服務提供者和患者方面，具有得天獨厚的優勢。」</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>諾華製藥(NVS)將以31億美元收購Anthos</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n諾華製藥(NVS)將以31億美元收購Anthos\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086022552\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">金吾財訊 </p>\n<p class=\"h-time smaller\">2025-02-11 14:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>金吾財訊 | <a href=\"https://laohu8.com/S/BX\">黑石</a>集團(BX)旗下黑石生命科學公司和Anthos治療公司宣佈<a href=\"https://laohu8.com/S/NVS\">諾華</a>製藥(NVS)將以31億美元收購Anthos，交易預計將於2025年上半年完成。Anthos股東將獲得9.25億美元的首付款。</p><p>對於諾華而言，此次收購是其在心血管領域的重要佈局。諾華在心血管領域根基深厚，而阿貝拉西單抗的加入有望進一步豐富其產品線，為全球數百萬面臨中風高風險的心房顫動患者提供更有效的治療選擇。</p><p>Anthos 首席執行官 Bill Meury 表示：「諾華在心血管領域的深厚底蘊，使其在推進阿貝拉西單抗的臨牀開發以及將這一創新產品帶給醫療服務提供者和患者方面，具有得天獨厚的優勢。」</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"285290","article_id":"2510841878","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20210625/ZTg0OWM0M2E2YjcwZGM0MTQ1YzIxNjI0NjAwNDk2ODM0.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510841878","pubTimestamp":1739257014,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾財訊","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾財訊 | 黑石集團(BX)旗下黑石生命科學公司和Anthos治療公司宣佈諾華製藥(NVS)將以31億美元收購Anthos，交易預計將於2025年上半年完成。Anthos股東將獲得9.25億美元的首付款。對於諾華而言，此次收購是其在心血管領域的重要佈局。諾華在心血管領域根基深厚，而阿貝拉西單抗的加入有望進一步豐富其產品線，為全球數百萬面臨中風高風險的心房顫動患者提供更有效的治療選擇。Anthos 首席執行官 Bill Meury 表示：「諾華在心血管領域的深厚底藴，使其在推進阿貝拉西單抗的臨牀開發以及將這一創新產品帶給醫療服務提供者和患者方面，具有得天獨厚的優勢。」","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4532":"文艺复兴科技持仓","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BX":"黑石","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","NVS":"诺华","BK4578":"CAR-T","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4135":"资产管理与托管银行","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","01477":"欧康维视生物-B","BK4588":"碎股","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4007":"制药","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK1191":"制药","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"Novartis Pharmaceuticals (NVS) to acquire Anthos for $3.1 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"NVS":1,"BX":0.9},"content_text":"金吾財訊 | 黑石集團(BX)旗下黑石生命科學公司和Anthos治療公司宣佈諾華製藥(NVS)將以31億美元收購Anthos，交易預計將於2025年上半年完成。Anthos股東將獲得9.25億美元的首付款。對於諾華而言，此次收購是其在心血管領域的重要佈局。諾華在心血管領域根基深厚，而阿貝拉西單抗的加入有望進一步豐富其產品線，為全球數百萬面臨中風高風險的心房顫動患者提供更有效的治療選擇。Anthos 首席執行官 Bill Meury 表示：「諾華在心血管領域的深厚底藴，使其在推進阿貝拉西單抗的臨牀開發以及將這一創新產品帶給醫療服務提供者和患者方面，具有得天獨厚的優勢。」","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}